Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Frank Y LinAustin StuckertCandise TatMark WhiteLucia RuggieriHuimin ZhangBirju MehtaNatalia LaptevaZhuyong MeiAngela MajorSachin G ThakkarThomas ShumKathan ParikhMeng-Fen WuHolly B LindsayLauren SchererMeghan ShekarPatricia BaxterNicholas WangBambi GrilleyKaren MoellerJohn HicksAngshumoy RoyJamie N AnastasFatema MalbariGuillermo AldaveMurali ChintagumpalaSusan BlaneyDonald Williams ParsonsMalcolm K BrennerHelen E HeslopCliona M RooneyBilal OmerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Intravenous GD2.CARTs with and without C7R were well tolerated. Patients treated with C7R-GD2.CARTs exhibited transient improvement of neurologic deficits and increased circulating cytokines/chemokines. Treatment with C7R-GD2.CARTs represents a novel approach warranting further investigation for children with these incurable CNS cancers.